摘要:
A process for removing osmium from an aqueous solution of nucleosides comprising adding hydrogen sulfide, an aromatic pi base such as pyridine, and a mineral acid. The osmium is precipitated out of solution.
摘要:
Synthesis of the triol of formula (I) or its amine-protected derivative from a cyclopentene of the formula (II) or its amine-protected derivative: ##STR1## via steps including oxidation to the aldehyde, migration of the double bond, reduction of the aldehyde moiety back to the alcohol grouping and 1,2-cis-dihydroxylation of the double bond.
摘要:
Synthesis of the triol of the following formula (I) from an alcohol of the formula (IV): ##STR1## via steps including protecting and then cyanating the alcohol to yield a cyanide, isomerization of the double bond, hydrolysis followed by reduction of the cyanide back to an alcohol and cis-dihydroxylation of the double bond.
摘要:
The compound 1,8-diazabicyclo[5.4.0]undec-1(7)-enium cyanide is the reaction product of acetone cyanohydrin and 1,8-diazabicyclo [5.4.0]undec-7-ene.
摘要:
A kinetic resolution of pyridazinones of the following formula (A): ##STR1## where R.sup.1 is alkyl by enzymatic hydrolysis results in good optical purity of the phenolic product. This is significant considering the distance in the molecule (A) from the C-5 chiral center to the site of hydrolysis.
摘要:
The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceutically acceptable carrier are further provided. Compositions also include diagnostic assay-type probes comprising a novel A1 adenosine receptor antagonist of formula (I) that is labeled or conjugated with radioactive or non-radioactive material. Methods for treating A1 adenosine receptor related disorders comprising administering an A1 adenosine receptor antagonist of formula (I) are also disclosed. The novel A1 adenosine receptor antagonist compositions of formula (I) find further use in diagnostic and imaging methods. wherein R3 is Alk14ArR16, and wherein Alk14 is C1-8 straight or branched alkylene or alkenylene.
摘要翻译:本发明提供新颖的腺苷受体拮抗剂,更具体地,提供式(I)的Aβ1腺苷受体拮抗剂。 进一步提供了包含式(I)的A 1 +腺苷受体拮抗剂和药学上可接受的载体的药物组合物。 组合物还包括诊断测定型探针,其包含用放射性或非放射性物质标记或缀合的式(I)的新的A 1 N 2腺苷受体拮抗剂。 还公开了治疗A 1 N 2腺苷受体相关病症的方法,其包括施用式(I)的Aβ1 N 2腺苷受体拮抗剂。 式(I)的新型A 1 N 1腺苷受体拮抗剂组合物进一步用于诊断和成像方法。 其中R 3是Alk 14 ArR 16,并且其中Alk 14是C 1-8烷基, / SUB>直链或支链亚烷基或亚烯基。
摘要:
A method for the synthesis of 2',3'-dideoxycytidine comprising a novel procedure of bromoacetylating cytidine to yield novel intermediates which are subsequently reduced and hydrogenated by novel procedures to yield 2',3'-dideoxycytidine.
摘要:
Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydrogen or fluorine are described. The compounds of formula I are useful as agents in the treatment of disease states characterized by metabolic calcium deficiencies. Examplary of such disease states are osteoporosis and renal osteodystrophy.
摘要:
Compounds of pyridinium salts and methods of their use in medicine, particularly in the prophylaxis and treatment of inflammatory conditions, infectious conditions, as well as immune disorders are disclosed. The present invention also relates to methods of controlling fungi and/or bacteria.
摘要:
The present invention includes compounds of pyridinium salts and methods of their use for industrial uses. The present invention also relates to methods of controlling fungi and/or bacteria. The present invention may also be used to control insects.